Clinical trials: Neoplasms，Non-Small Cell Lung Cancer
Advanced Solid Tumors, Head and Neck Cancer
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- FPA008-003 (NCT02526017)
- Testing
- Cabiralizumab, Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 313 people
- Sponsor
- Five Prime Therapeutics, Inc.
Lung Cancer
Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)
In this study, effects of γδT cells on human non small lung cancer ( without EGFR mutation) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.
- Trial name
- NCT02425748
- Testing
- DC-CIK, γδ T Cell, γδ T/DC-CIK cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Non-Small Cell Lung Cancer
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
EGFR-TKI has firmly established itself as a first-line treatment for advanced lung cancer with EGFR-sensitive mutations, and the ADAURA study has added to its indications for use as postoperative adjuvant therapy in early- and…
- Trial name
- NCT05987826
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Spinal Metastases, Non-Small-Cell Lung Cancer Metastatic
Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
The purpose of this study is to learn whether our own made predictive algorithm can be used as a clinical practical decision support for patients with NSCLC spinal metastasis.
- Trial name
- NCT03363685
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Ruijin Hospital
Non Small Cell Lung Cancer
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
The primary aim of this single arm, phase II study is to determine the efficacy of the combination therapy Pembrolizumab/Lenvatinib regarding the rate of major pathological response (MPR-Rate).
- Trial name
- INNWOP1 (NCT04875585)
- Testing
- neoadjuvant therapy with Pembrolizumab/Lenvatinib, Surgery, Adjuvant Treatment Phase
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Medical University Innsbruck
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back.
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03971474
- Testing
- Docetaxel, Gemcitabine, Gemcitabine Hydrochloride
- Where
- 889 sites in United States
- Volunteers
- 166 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
Non Small Cell Lung Cancer, Brain Metastases
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
- Trial name
- NCT06702826
- Testing
- Cadonilimab combined with SRS
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Rongrong Zhou
Carcinoma, Non-Small-Cell Lung
Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer
The indication of chemotherapy of 2nd line treatment in advanced non small cell lung cancer is now well established. The two treatments of reference are pemetrexed (alimta) and docetaxel (taxotere).
- Trial name
- NCT00284778
- Testing
- Alimta®, Taxotere®
- Where
- 18 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Limoges
Non-Small Cell Lung Cancer
20-Fr Versus 24-Fr Chest Drains After Uniportal VATS Lobectomy for NSCLC
This randomized clinical trial compared two different chest drain sizes, 20 Fr and 24 Fr, in patients undergoing lung lobectomy for lung cancer.
- Trial name
- DRAIN2024 (NCT07827885)
- Testing
- 20-Fr Thoracic Drain, 24-Fr Thoracic Drain
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Non-small Cell Lung Cancer, Gastric Cancer
Early Palliative Care on Quality of Life of Advanced Cancer Patients
This study compares two types of care - Standard Oncology Care (SOC) and SOC with early palliative care (EPC) (started within 8 weeks after diagnosis of advanced disease) to see which is better for improving the quality of life…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- NCT02988635
- Testing
- Early Palliative Care
- Volunteers
- 281 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Breast Cancer, Lung Cancer
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
The purpose of this study is to test the combination of an experimental drug known as MGCD0103 given along with an FDA-approved drug called docetaxel.
- Conditions
- Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT00511576
- Testing
- MGCD0103 & Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Mirati Therapeutics Inc.
Nonsmall Cell Lung Cancer Stage
SBRT for Ultra-Central NonSmall Cell Lung Cancer
The goal of this clinical trial is to find out if Five-fraction CyberKnife stereotactic body radiation therapy (SBRT) with real-time Synchrony® motion tracking can treat ultra-central nonsmall cell lung cancer while reducing the…
- Trial name
- STELLAR IIT (NCT07852247)
- Testing
- SBRT
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Georgetown University
Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
This pilot clinical trial studies the effects of stereotactic body radiation therapy followed by surgery in treating patients with stage I-IIIA non-small cell lung cancer.
- Conditions
- Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03348748
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Early Diagnosis and Treatment of Sleep Disordered Breathing in Lung Cancer
Sleep-disordered breathing at night is a common medical problem. It leads to daytime fatigue, impairment in concentration and daily activities, and a higher risk of cardiovascular disease and life-threatening events.
- Trial name
- NCT03443908
- Testing
- CPAP
- Where
- United States
- Sponsor
- Mark M. Fuster, MD
Non Small Cell Lung Cancer
Erlotinib and Sunitinib in NSCLC
To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.
- Trial name
- NCT00581789
- Testing
- erlotinib, sunitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
Advanced/Recurrent Non-small-cell Lung Cancer
A Study of ARQ 197 in Combination With Erlotinib
This is a phase I study to determine the safety, tolerability and recommended phase II dose of ARQ 197 given in combination with erlotinib as primary endpoints in CYP2C19 poor metabolizer patients with advanced/recurrent…
- Trial name
- NCT01251796
- Testing
- ARQ 197 and Erlotinib
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Trial name
- NCT04272203
- Testing
- ABBV-184
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- AbbVie
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
The present study has 5 parts. In Parts A and A1, the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated from 1 to 10 mg/kg to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for…
- Trial name
- KEYNOTE-001 (NCT01295827)
- Testing
- Pembrolizumab
- Volunteers
- 1,260 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.